Recent approaches to treating SMA have been highly effective in increasing SMN protein production by either modifying SMN2 gene splicing with nusinersen and risdiplam, or SMN gene replacement therapy (onasemnogene abeparvovec-xioi). Here, SMN2 is linked to proximal spinal muscular atrophy.